Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Issue 5 (30th July 2013)

• Record Type: Journal Article
• Authors: Yokoyama, S.; Takahashi, S.; Kawakami, Y.; Hayes, C. N.; Kohno, H.; Kohno, H.; Tsuji, K.; Aisaka, Y.; Kira, S.; Yamashina, K.; Nonaka, M.; Moriya, T.; Kitamoto, M.; Aimitsu, S.; Nakanishi, T.; Kawakami, H.; Chayama, K.
• Is Part Of: Journal of viral hepatitis. Volume 21:Issue 5(2014)
• Page Start: 348
• Page End: 356
• Publication Date: 2013-07-30
• Subjects: Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12146
• Languages: English
• ISSNs: 1352-0504

Abstract

<abstract abstract-type="main" id="jvh12146-abs-0001"> <title>Summary</title> <p>Chronic HCV–infected patients tend to have vitamin D deficiency, suggesting that vitamin D supplementation may enhance the efficacy of treatment with pegylated interferon (PEG‐IFN) and ribavirin (RBV). We therefore assessed the effects of vitamin D supplementation on viral response to PEG‐IFN/RBV. Eighty‐four patients with HCV genotype 1b were randomized, 42 to oral vitamin D supplementation (1000 IU/day) and 42 to nonsupplementation (control), from week 8 to the end of PEG‐IFN/RBV therapy. The primary end point was undetectable HCV RNA at week 24 (viral response [VR]). VR rate at week 24 was significantly higher in the vitamin D than in the control group (78.6% <italic>vs</italic> 54.8% <italic>P</italic> = 0.037). Adverse events were similar in both groups. When patients were subdivided by IL28B SNP rs8099917 genotype, those with the TT genotype group showed a significantly higher VR rate at week 24 with than without vitamin D supplementation (86.2% <italic>vs</italic> 63.3% <italic>vs P</italic> = 0.044). Although patients with the TG/GG genotype, who were relatively resistant to PEG‐IFN treatment, had similar VR rates at week 24 with and without vitamin D supplementation, the decline in viral load from week 8 to week 24 was significantly greater with than without vitamin D supplementation. Multivariate analysis showed that rs8099917 genotype and vitamin D supplementation contributed significantly to VR at week 24. SVR rates were similar in the vitamin D and control groups [64.3% (27/42) <italic>vs</italic> 50% (21/42), <italic>P</italic> = 0.19]. Vitamin D supplementation may enhance the effects of PEG‐IFN/RBV in HCV genotype 1b–infected patients.</p> </abstract>